NS Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1999-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.nspharma.com
Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Phase 2
Completed
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Drug: PlaceboDrug: NS-065/NCNP-01
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2021-12-07
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT02740972
- Locations
- 🇺🇸
UC Davis, Sacramento, California, United States
🇺🇸Lurie Children's Hospital, Chicago, Illinois, United States
🇺🇸University of Florida Health, Gainesville, Florida, United States
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Phase 1
Completed
- Conditions
- Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
- Interventions
- Drug: NS-018
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT01423851
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸UC San Diego Moores Cancer Center, San Diego, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of NS-9 in Patients With Liver Metastases
Phase 1
Completed
- Conditions
- Liver NeoplasmsNeoplasm MetastasisLocal Neoplasm Recurrences
- First Posted Date
- 2004-10-11
- Last Posted Date
- 2005-11-11
- Lead Sponsor
- NS Pharma, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00094003
- Locations
- 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath